Wei Yen Chan

Wei Yen Chan serves as a Conjoint Associate Lecturer at Macquarie Medical School, Macquarie University, while practicing as an Oncologist at Macquarie University Hospital. Holding a Doctor of Philosophy through the Faculty of Medicine, Health and Human Sciences, Chan maintains active research output with an h-index of 15 based on Scopus citations.

Research focuses primarily on cancer immunotherapy and liquid biopsy technologies, with specialization in circulating tumor DNA (ctDNA) analysis. Key areas include neoadjuvant immunotherapy response monitoring in melanoma, chemoimmunotherapy applications for lung cancer with brain metastases, and technical optimization of cell-free DNA pre-amplification methods. The research fingerprint shows dominant activity in Immunotherapy (100%), Circulating Tumor DNA (100%), and Melanoma (50%) within Pharmacology and Medicine disciplines.

Recent publication trends demonstrate strong translational focus, with 2024-2025 outputs appearing in Journal of Experimental and Clinical Cancer Research, Frontiers in Oncology, and Biomolecules. Three peer-reviewed articles include significant contributions to melanoma recurrence prediction (11 Scopus citations) and brain metastasis treatment registries (4 Scopus citations), featuring collaborative work with leading Australian cancer researchers including Long GV and Scolyer RA.

Awards and recognition include an h-index of 15 with 2 citations tracked through Macquarie's Pure system, plus media coverage from 1 news outlet and social media mentions across 3 X (Twitter) posts. Research has attracted 51 total Mendeley readers and 30 Pure downloads.

Current research involves active collaboration within Australia's oncology network, particularly in ctDNA dynamics and immunotherapy response prediction. The work bridges clinical practice at Macquarie University Hospital with academic research through Macquarie Medical School, focusing on improving cancer detection and treatment monitoring through liquid biopsy innovations.